Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Horizon National

Broadcom

They're not exactly names you think of for income, but that doesn't make them bad income options.

Love Dividends? Here Are 3 Stocks You Might Want to Buy

AbbVie

Algonquin Power & Utilities

British American Tobacco

Canadian Imperial Bank of Commerce

Canadian Natural Resources

Chevron

Enbridge

Novartis

Pembina Pipeline

Sanofi

AT&T

TC Energy

Kiplinger "insights for investors" online, first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 5/25/21 revealed 13 yields ripe for picking. These International “Dividend Aristocrats,” have raised dividends at least five straight years (Canadian) 10 years (European Union) or 25 years (U.S. companies).

The 91 'Best Dividend Stocks On Earth' For June

DUBLIN, Ohio & INDIANAPOLIS--(BUSINESS WIRE)--Cardinal Health and Telix launch Gallium Awareness campaign with release of White-Paper: “Moving beyond the Myth”

Cardinal Health and Telix Launch Gallium Awareness Campaign With Release of White-Paper: “Moving Beyond the Myth”

Archer-Daniels-Midland Company

Aflac

Amcor Plc

Atmos Energy

Franklin Resources

Cincinnati Financial

Con Ed

Expeditors International of Washington

General Dynamics

Kimberly-Clark

Sherwin-Williams

Stanley Black & Decker

Stock valuations are in the clouds, but several Dividend Aristocrats can be had at cheaper prices than their blue-chip peers.

15 Dividend Aristocrats You Can Buy at a Discount

AmerisourceBergen

CVS Health

McKesson

Rite Aid

Walgreens

Shares of drug retailers including Walgreens Boots Alliance  and CVS dropped on Wednesday, as Amazon was reported to be looking at options to set up physical pharmacy locations in the US.  Talks at Amazon about setting up standalone pharmacies are mostly exploratory and there are no firm plans to open physical locations, three people familiar with the matter told Insider.  Such a move would be part of a plan by the online retail behemoth to earn a larger share of the country's $370 billion prescription drug market.

Pharmacy stocks tumble on report Amazon is weighing a push into physical pharmacies (AMZN, CVS, RAD, WAG, CAH, MCK, ABC)

CAH has been a long-term disappointment to investors. The Wall Street consensus is neutral-to-bullish, with expected 12-month price appreciation of 11.4-15.8%.

Cardinal Health Can Generate Impressive Income

Energizer Holdings

Quaker Chemical

Lincoln Electric Hlds

Oshkosh

As investors await the Fed minutes to be released Wednesday amid massive consumer earnings cues, make the most of this market with today's Top Buys from Q.ai's artificial intelligence.

Energizer Holdings Inc Among Top Buys Amid Market Volatility

Cisco Systems

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Illinois Tool Works

Johnson & Johnson

Kinder Morgan

Leggett & Platt

Occidental Petroleum

Procter & Gamble

Philip Morris

Schlumberger

Total

ViacomCBS

Each month, we share the amount of dividend income we received and compare the results to the previous year. Until the stock market was stabilized and the first stimulus bill was passed, there were a lot of undervalued dividend stocks that we were able to add to our portfolios.

Dividend Income Summary: Bert's April 2021 Summary

Becton, Dickinson and Co.

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

People's United Financial

Dividend Aristocrats can be a great choice for investors looking for reliable income and stocks that can outperform during a recession. Not all Dividend Aristocrats are necessarily attractive at the same time, however.

10 Of The Best Value Picks Among Dividend Aristocrats

PepsiCo

PepsiCo, Cardinal Health, and Baxter were among the large companies that declared dividend increases this week.

PepsiCo, Cardinal Health, and 3 Other Companies That Raised Their Dividends

Cardinal Health projected making capital expenditures in this fiscal year of between $400 million and $450 million; these investments will be primarily for information technology and infrastructure. On the IT side, Cardinal has invested in an advanced visibility solution.

Cardinal Health Invests In An Advanced Visibility Solution

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q3 2021 Results - Earnings Call Transcript

Cardinal Health (NYSE: CAH) reported the third-quarter FY21 adjusted EPS of $1.53, which missed the consensus estimate of $1.55. The earnings dropped 6% Y/Y, reflecting a higher non-GAAP effective tax rate.

Cardinal Health Stock Tumbles After Q3 Earnings Fall Short Of Expectations; Narrowed FY21 Adjusted EPS Guidance

Cardinal (CAH) delivered earnings and revenue surprises of -3.16% and -1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q3 Earnings and Revenues Lag Estimates

Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.

Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates

Cardinal Health Inc. shares slid 8.8% in premarket trade Thursday, after the drug distributor posted weaker-than-expected earnings for its fiscal third quarter and lowered the top end of its guidance. The company said net income fell to $119 million, or 40 cents a share, in the quarter to March 31, down from $350 million, or $1.19 a share, in the year-earlier period.

Cardinal Health shares slide 8.8% premarket after earnings fall short of esimates

DUBLIN, Ohio, May 6, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third-quarter fiscal year 2021 revenue of $39.3 billion, in-line with the third quarter of last year. Third-quarter GAAP operating earnings decreased 16% to $473 million, primarily due to the write-down of the net assets held for sale from the planned divestiture of the Cordis business.

Cardinal Health reports third-quarter results for fiscal year 2021

Chubb

Clorox

Costco

Lockheed Martin

Medtronic

Northrop Grumman

Travelers

Dividend stocks continue to amaze. If the goal is to produce a passive income stream that will one day cover our expenses, making sure that income stream grows is critical.

6 Dividend Increases Expected In May 2021

News for Cardinal Health Stock (CAH)